Angiotensin II: Multitasking in the brain

Journal of Hypertension

Volumn 24, Issue SUPPL. 1, 2006, Pages

  Saavedra, Juan M ^a   Benicky, Julius ^a   Zhou, Jin ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Angiotensin receptor blockers; Anxiety; Brain inflammation; Brain ischemia; Corticotropin releasing factor; Renin angiotensin system; Stress; Stroke; Vasopressin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BENZODIAZEPINE RECEPTOR; CANDESARTAN; CAPTOPRIL; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; VASOPRESSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA;

BRAIN CIRCULATION; BRAIN ISCHEMIA; COGNITION; HUMAN; INFLAMMATION; MOOD DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STOMACH ULCER; STRESS; ANIMAL; BRAIN; GENETICS; MENTAL STRESS; PHYSIOLOGY; SECRETION;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ARGININE VASOPRESSIN; BRAIN; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; COGNITION; CORTICOTROPIN-RELEASING HORMONE; HUMANS; MOOD DISORDERS; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; STRESS, PSYCHOLOGICAL;

EID: 33745582899     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000220418.09021.ee     Document Type: Review

References (40)

1. Saavedra JM. Brain and pituitary angiotensin. Endocr Rev 1992; 13:329-380.
2. Saavedra JM. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 2005; 25:485-512.
3. 1 receptor antagonists. Regul Pept 2005; 128:227-238.
4. 2) in rat brain. Am J Physiol Regul Integr Comp Physiol 1991; 261:R209-R216.
5. 1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004; 25:1726-1731.
6. Salzet M, Deloffre L, Breton C, Vieau D, Schoofs L. The angiotensin system elements in invertebrates. Brain Res Rev 2001; 36:35-45.
7. Faraci FM, Heistad DD. Regulation of large cerebral arteries and cerebral microvascular pressure. Circ Res 1990; 66:8-17.
8. 1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000; 31:2478-2486.
9. Saavedra JM, Nishimura Y. Angiotensin and cerebral blood flow. Cell Mol Neurobiol 1999; 19:553-573.
10. Edvinsson L, Hardebo JE, Owman C. Effects of angiotensin II on cerebral blood vessels. Acta Physiol Scand 1979; 105:381-383.
11. 1 receptors. Brain Res 2000; 871:29-38.
12. Ito T, Nishimura Y, Saavedra JM. Pre-treatment with candesartan protects from cerebral ischemia. J Renin Angiotensin Aldosterone Syst 2001; 2:174-179.
13. 1 antagonist. Stroke 2002; 33:2297-2303.
14. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation and fibrosis. Hypertension 2001; 38:581-587.
15. 1 receptor inhibition. J Cereb Blood Flow Metab 2003; 23:371-380.
16. Chou TC, Yen MH, Chi-Yuan L, Ding YA. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 1998; 31:643-648.
17. Amin-Hanjani SH, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001; 32:980-986.
18. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide to production via membrane NADH/NADPH oxidase activation. J Clin Invest 1996; 97:1916-1923.
19. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100:2153-2157.
20. Zhou J, Ando H, Macova M, Dou J, Saavedra JM. Angiotensin II AT(1) receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab 2005; 25:878-886.
21. Xang G, Xi ZX, Wan Y, Wang H, Bi G. Changes in circulating and tissue angiotensin II during acute and chronic stress. Biol Signals 1993; 2:166-172.
22. 2 receptors. Neuroendocrinol 2002; 75:227-240.
23. 1 receptor antagonist decreases the hypothalamic-pituitary-adrenal response to stress. Endocrinology 2001; 142:3880-3889.
24. Castrén E, Saavedra JM. Repeated stress increases the density of angiotensin II binding sites in the rat paraventricular nucleus and subfornical organ. Endocrinology 1988; 122:370-372.
25. Saavedra JM, Armando I, Bregonzio C, Juorio A, Macova M, Pavel J, Sanchez-Lemus E. A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology 2005; (Epub ahead of print).
26. 1 receptor antagonism prevent stress-induced gastric injury. Am J Physiol Gastrointest Liver Physiol 2003; 285:G414-G423.
27. 2 receptor gene-disrupted mice. Neuroendocrinology 2002; 76:137-147.
28. Okuyama S, Sakagawa T, Chaki S, Imagawa Y, Ichiki T, Inagami T. Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor. Brain Res 1999; 821:150-159.
29. A) receptor subunits and benzodiazepine binding: significance to clinical syndromes and their treatment. Br J Biomed Sci 2001; 58:111-121.
30. Barnes NM, Costall B, Kelly ME, Murphy DA, Naylor RJ. Anxiolytic-like action of DuP753, a non-peptide angiotensin II receptor antagonist. Neuroreport 1990; 1:20-21.
31. Gard PR, Mandy A, Sutcliffe MA. Evidence of a possible role of altered angiotensin function in the treatment, but not aetiology, of depression. Biol Psychiatry 1999; 45:1030-1034.
32. Zubenko GS, Nixon RA. Mood-elevating effect of captopril in depressed patients. Am J Psychiatry 1984; 141:110-111.
33. Deicken RF. Captopril treatment of depression. Biol Psychiatry 1986; 21:1425-1428.
34. Germain L, Chouinard G. Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol Psychiatry 1998; 25:489-493.
35. Gard PR. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets 2004; 8:7-14.
36. Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F. Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data. J Neurol Sci 2002; 203:147-151.
37. Tedesco MA, Ratti G, Mennella S, Manzo G, Grieco M, Rainone AC, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999; 12:1130-1134.
38. Fogari R, Preti P, Mugellini A, Derosa G, Poletti L, Banderali A, et al. Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients. Am J Hypertens 2002; 15:A36.
39. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, Müller-Spahn F. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging 2001; 22:541-546.
40. Saavedra JM, Pavel J. Angiotensin II AT1 receptor antagonists inhibit the angiotensin-CRH-AVP axis and are potentially useful for the treatment of stress-related and mood disorders. Drug Devel Res 2005; 65:237-269.